ROSEN urges Telix Pharmaceuticals investors to act before Jan. 9, 2026 deadline

Global law firm Rosen Law Firm — the first to file a securities‑class‑action suit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) — is urging anyone who bought Telix stock between February 21, 2025 and August 28, 2025 to secure legal counsel before the court deadline of January 9, 2026. Under the lawsuit, investors may be entitled to compensation without paying any upfront fees, thanks to a contingency‑fee arrangement. Those wishing to participate — or to apply to serve as lead plaintiff representing the class — must act by the January date. The legal challenge alleges that, during the “class period,” Telix misled investors by overstating progress on its prostate‑cancer therapy candidates, and exaggerating the quality of its supply chain and partnerships. According to the complaint, these statements distorted the company’s business outlook, and when the truth emerged, shareholders suffered losses. Rosen Law Firm highlights that many notice‑issuers of class‑action suits lack the experience, resources, or track record of a firm like theirs — which has repeatedly recovered hundreds of millions for investors. If you held Telix shares during the relevant period and want to learn more or join the class action, you’re encouraged to contact Rosen via their website or by calling Phillip Kim, Esq. (toll‑free 866‑767‑3653) or emailing . #Telix #ClassAction #InvestorRights #RosenLawFirm #SlimScan #GrowthStocks #CANSLIM